Weight-loss drugs like semaglutide, developed by Novo Nordisk and Eli Lilly, are showing promising signs of slowing biological aging. Studies using molecular "aging clocks" indicate that patients taking these GLP-1 medications experience a reduction in their biological age, with differences ranging from two to four years depending on the clock and tissue analyzed. These findings suggest that GLP-1 drugs may act as geroprotectors, potentially impacting the fundamental processes of aging and improving health span. AI
IMPACT These findings could spur further research into GLP-1 drugs as longevity treatments and influence the development of new geroprotective therapies.
RANK_REASON The item discusses findings from drugmakers about the effects of GLP-1 drugs on biological aging, supported by researchers in the field of aging clocks. [lever_c_demoted from research: ic=1 ai=0.4]
Read on MIT Technology Review →
- Aging Research & Drug Discovery
- Alejandro Aguayo-Orozco
- Eli Lilly and Company
- GLP-1s
- Harvard University
- Novo Nordisk
- Ozempic
- semaglutide
- Steve Horvath
- University of California, Los Angeles
- Vadim N. Gladyshev
- Wegovy
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →